Messages in brief
Information on the introduction of safety features in the form of individual identification marks on each individual drug package. (Update)
For more information on this topic, follow the link to the security features.
Valsartan / Sartan-containing drugs: Pharmaceutical companies to review manufacturing processes to avoid occurrence of nitrosamine-containing impurities
Revision of the EMA “Guideline on the environmental risk assessment (ERA) of human medicines”
New guideline on assessment and control of mutagenic impurities in veterinary medicinal products
National Immunization Schedule 2019
link: https://www.sozialministerium.at/site/Gesundheit/Kran…
German and Austrian drug agencies intensify cooperation on regulation of allergen products
A team from the Austrian Federal Office for Safety in Health Care (BASG) was a guest at the Paul Ehrlich Institute (PEI) on Jan. 14, 2019. The aim was…
Falsification suspicion of parallel-imported "ALIMTA 500 mg powder for the preparation of a concentrate for infusion solution".
Situation in Austria The Federal Office for Safety in Health Care (BASG) has received information that several packages of the drug "ALIMTA 500 mg…
Changes in the declaration procedure for the medical device levy 2018
The procedure for declaring duties for the year 2018 will change fundamentally as of 01.01.2019. As of this date, the self-declaration must be…
Fluoroquinolones: restrictions on use
Action at EU level The European Medicines Agency (EMA) has scientifically reassessed the serious, disabling and potentially permanent side effects of…
Round table on "Availability of medicines in Austria" (1)
On November 27, 2018 a big "round table" took place on the topic of availability of medicines in Austria. At the top-class event, which was organised…
